KILITCH DRUGS (INDIA) LTD. - 524500 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
We hereby inform that the company has received intimation regarding loss of share certificate by Narayan Shet N Verekar18-05-2024
18-05-2024
KILITCH DRUGS (INDIA) LTD. - 524500 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
We hereby inform you that the Company has issued duplicate share certificate to Mr. Manubhai Shah18-05-2024
KILITCH DRUGS (INDIA) LTD. - 524500 - Compliances-Reg.24(A)-Annual Secretarial Compliance
Please find enclosed herewith the annual secretarial compliance report for the financial year ended 31st March, 202414-05-2024
KILITCH DRUGS (INDIA) LTD. - 524500 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation to stock exchange regarding loss of share certificate by the shareholders03-05-2024
KILITCH DRUGS (INDIA) LTD. - 524500 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation to stock exchanges regarding issuance of duplicate share certificate03-05-2024
KILITCH DRUGS (INDIA) LTD. - 524500 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyKILITCH DRUGS (INDIA) LTD. 2CIN NO.L24239MH1992PLC066718 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY NA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Pushpa Nyoupane Designation: Company Secretary and Compliance Officer EmailId: [email protected] Name of the Chief Financial Officer: Sunil Jain Designation: Chief Financial Officer EmailId: [email protected] Date: 29/04/2024 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.29-04-2024
KILITCH DRUGS (INDIA) LTD. - 524500 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of Issue of Duplicate share certificate to shareholders. Details attached.24-04-2024
KILITCH DRUGS (INDIA) LTD. - 524500 - Certificate Under Regulation 40(10) Of SEBI(Listing Obligations And Disclosure Requirements) Regulations, 2015
Enclosing the certificate received from Practicing Company Secretary under regulation 40(10) of SEBI (Listing Obligations and Disclosure Requirements) Regulatitons, 201515-04-2024
US FDA Issues Warning Letter To Kilitch Healthcare For Navi-Mumbai Plant
The warning letter summarises significant violations of current good manufacturing practice regulations for finished pharmaceuticals at the Navi-Mumbai plant, which produces finished pharmaceuticals.11-04-2024
KILITCH DRUGS (INDIA) LTD. - 524500 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Compliance Certificate under regulation 74(5) of SEBI (DP) Regulation, 201810-04-2024